GeneDx Holdings Corp.
WGS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.54 | 0.00 | 0.01 | -0.02 |
| FCF Yield | -1.64% | -277.99% | -374.00% | -43.82% |
| EV / EBITDA | -1,664.93 | -0.64 | -0.07 | -0.52 |
| Quality | ||||
| ROIC | -6.27% | -49.34% | -148.82% | -97.79% |
| Gross Margin | 63.64% | 44.43% | -11.40% | -7.82% |
| Cash Conversion Ratio | 0.55 | 1.02 | 0.58 | 0.78 |
| Growth | ||||
| Revenue 3-Year CAGR | 9.18% | -1.54% | 9.38% | 2.65% |
| Free Cash Flow Growth | 81.71% | 44.27% | -57.88% | -68.84% |
| Safety | ||||
| Net Debt / EBITDA | -24.57 | -0.15 | 0.15 | 1.67 |
| Interest Coverage | -7.66 | 0.00 | -208.19 | -157.37 |
| Efficiency | ||||
| Inventory Turnover | 10.43 | 12.82 | 19.13 | 6.84 |
| Cash Conversion Cycle | 53.83 | 54.39 | 22.24 | 27.77 |